SyntheticMR announced that their quantitative imaging software solution SyMRI has received regulatory approval in Malaysia and can now be sold and distributed in this market. SyMRI provides multiple contrast weighted images and quantitative information about the patient in a single 5-minute scan, enabling users to speed up their imaging workflow and add objective decision support to their practice.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.7 SEK | +1.09% | -.--% | +4.14% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.14% | 106M | |
+4.71% | 32.58B | |
+16.75% | 7.65B | |
+23.49% | 3.92B | |
-15.80% | 3.19B | |
-27.19% | 1.26B | |
-33.58% | 1.14B | |
-33.74% | 926M | |
+1.56% | 908M | |
-23.93% | 859M |
- Stock Market
- Equities
- SYNT Stock
- News SyntheticMR AB
- SyntheticMR's SyMRI Software Receives Regulatory Approval in Malaysia